- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Maternal Health Inequities: Improving Access to Postpartum Depression Treatment
Douglas Weber, MD, explains how zuranolone has changed the landscape for postpartum depression treatment, addressing a gap in care within maternal health.
Zuranolone (Zurzuvae; Sage Therapeutics/Biogen), the first oral medication approved by the FDA for postpartum depression (PPD), became available at the end of last year, offering physicians and patients an effective and more convenient treatment option for managing PPD.
In this episode of Managed Care Cast, hosted by the Center on Health Equity & Access, Douglas Weber, MD, OB-GYN at MomDoc, explained why this therapy has impacted maternal and postpartum care. Previously, treatment for PPD was limited to intravenous (IV) administration of brexanolone (Zulresso) or commonly prescribed antidepressant medications which are not necessarily designed to address the hormonal components of PPD.
Leveraging AI and Community Health Workers to Boost Trial Access
January 4th 2025In this second part of our interview with Kasey Bond, MPH, NYU Langone Health, we discuss the contributions of community health workers to increasing clinical trial access and how technology—artificial intelligence (AI), in particular—can help to facilitate the process.
Read More
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
BeiGene’s Mehrdad Mobasher, MD, MPH, Discusses CLL Data, Pipeline Following ASH 2024
January 2nd 2025This interview will appear in the January 2025 issue of Evidence-Based Oncology, our annual recap of the American Society of Hematology Meeting and Exposition. After this article went to press, the company announced its ticker symbol on the Nasdaq will change today.
Read More
